Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study.
暂无分享,去创建一个
D. Podzamczer | C. Katlama | J. Gatell | A. Giacomelli | G. Guaraldi | J. Ordóñez‐Llanos | J. Connault | A. Pozniak | L. Assoumou | P. Domingo | M. Masiá | J. L. Sánchez-Quesada | M. Saumoy | E. Martínez | A. González-Cordón